H
Helio Elkis
Researcher at University of São Paulo
Publications - 115
Citations - 3381
Helio Elkis is an academic researcher from University of São Paulo. The author has contributed to research in topics: Schizophrenia & Positive and Negative Syndrome Scale. The author has an hindex of 27, co-authored 111 publications receiving 2812 citations. Previous affiliations of Helio Elkis include University of Toronto & Federal University of Rio de Janeiro.
Papers
More filters
Journal ArticleDOI
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D. Howes,Robert A. McCutcheon,Ofer Agid,Andrea de Bartolomeis,Nico J.M. van Beveren,Michael L. Birnbaum,Michael A P Bloomfield,Rodrigo A. Bressan,Robert W. Buchanan,William T. Carpenter,David J. Castle,Leslie Citrome,Zafiris J. Daskalakis,Michael Davidson,Richard J. Drake,Serdar M. Dursun,Bjørn H Ebdrup,Helio Elkis,Peter Falkai,W. Wolfgang Fleischacker,Ary Gadelha,Fiona Gaughran,B. Glenthøj,Ariel Graff-Guerrero,Jaime Eduardo Cecílio Hallak,William G. Honer,James L. Kennedy,Bruce J. Kinon,Stephen M. Lawrie,Jimmy Lee,F. Markus Leweke,James H. MacCabe,Carolyn B. McNabb,Herbert Y. Meltzer,Hans-Jürgen Möller,Shinchiro Nakajima,Christos Pantelis,Tiago Reis Marques,Gary Remington,Susan L. Rossell,Bruce R. Russell,Cynthia Siu,Takefumi Suzuki,Iris E. C. Sommer,David Taylor,Neil Thomas,Alp Üçok,Daniel Umbricht,James T.R. Walters,John M. Kane,Christoph U. Correll +50 more
TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.
Journal ArticleDOI
Treatment-Resistant Schizophrenia
TL;DR: This article updates and enhances a previous review of treatment-resistant schizophrenia with new evidence mainly derived from new studies, clinical trials, systematic reviews, and meta-analyses.
Journal ArticleDOI
Meta-analyses of Studies of Ventricular Enlargement and Cortical Sulcal Prominence in Mood Disorders: Comparisons With Controls or Patients With Schizophrenia
TL;DR: Patients with mood disorders have less ventricular enlargement than patients with schizophrenia, but this effect is small, which reinforces previous suggestions of the nonspecificity of structural brain changes in schizophrenia and mood disorders.
Journal ArticleDOI
Reduced Cortical Folding in Schizophrenia: An MRI Morphometric Study
Paulo C. Sallet,Helio Elkis,Tânia Maria Alves,José Roberto de Oliveira,Erlei Sassi,Cláudio Campi de Castro,Geraldo F. Busatto,Wagner F. Gattaz +7 more
TL;DR: These results from a larger patient group confirm a previous report of reduced cortical folding in schizophrenia patients and suggest a distinct pattern of abnormality between schizophrenia subtypes regarding the process of cerebral lateralization and are in agreement with the neurodevelopmental hypothesis of schizophrenia.
Journal ArticleDOI
Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review
Myrto Samara,Claudia Leucht,Mariska M Leeflang,Ion-George Anghelescu,Young-Chul Chung,Benedicto Crespo-Facorro,Helio Elkis,Kotaro Hatta,Ina Giegling,John M. Kane,Monica Kayo,Martin Lambert,Ching-Hua Lin,Hans-Jürgen Möller,José María Pelayo-Terán,Michael Riedel,Dan Rujescu,Benno Karl Edgar Schimmelmann,Alessandro Serretti,Christoph U. Correll,Stefan Leucht +20 more
TL;DR: Patients not even minimally improved by week 2 of antipsychotic treatment are unlikely to respond later and may benefit from a treatment change, and the test specificity was significantly moderated by a trial duration of <6 weeks, higher baseline illness severity, and shorter illness duration.